A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Who can take part

• Signed informed consent must be obtained prior to participation in the study
• Male or female as assigned at birth ≥ 18 years of age at the time of screening
• Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator
• Non-segmental vitiligo, as assessed at screening, as
• ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5
• ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60

Who cannot take part

• Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors
• Individual who previously attempted or completed depigmentation therapy for NSV
• Use of prohibited medication \& treatments. Other protocol-defined inclusion/exclusion criteria may apply
• Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations [such as piebaldism, Waardenburg, etc.], chemical- or druginduced leukoderma, etc.)
• Individuals unable or unwilling to follow the study procedures and/or to complete the study-related questionnaires